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Abstract
The emerging molecular understanding of cancer cell behavior is leading to increasing
possibilities to control unchecked cell growth and metastasis. On the other hand, development of
multifunctional drug carriers at the ‘nano’-scale is providing exciting new therapeutic strategies in
clinical management of cancer beyond the conventional cytotoxic drugs. A new frontier in this regard

IP

T

is the combinational use of complementary agents based on nucleic acids to overcome the limitations

CR

of conventional therapy. The existence of tightly-integrated cross-talk through multiple signaling and
effector pathways has been appreciated for some time, and the plasticity of such a network to overcome

US

one-dimensional intervention is stimulating development of combinational therapy. The objective of
this review is to underline the cutting edge technologies and opportunities employed in combination

AN

cancer therapy using nucleic acids therapeutics for successful clinical translation. Here, we provide a

M

detailed analysis of the multifunctional carriers designed for different types of payloads, surveying the
biomaterials used to construct the functional carriers. We then provide effective nucleic acid

ED

combinations employed to obtain more comprehensive outcomes, highlighting the critical factors

PT

involved in successful therapy. We conclude with an authors’ perspective on the future of
combinational therapy using nucleic acid therapeutics, articulating the main challenges to advance this

AC

CE

promising approach to the clinical realm.
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1.

Introduction
The conventional view of gene therapy, i.e., hereditary single gene defects corrected with

functional copies of the native gene, has been expanded to treatment of both acquired and infectious
diseases [1-4]. In the case of cancer, where hereditary and acquired defects, as well as infections agents
can cause cellular transformations, nucleic acid-based therapy is presenting an effective alternative to

IP

T

traditional chemotherapy. Therapeutic limitations of the latter approach have been appreciated, and

CR

they were attributed to robustness in signaling networks that includes redundancies, extensive crosstalk,
compensatory and neutralizing activities in disease-causing cells [5-8]. This realization has shifted the

US

drug development paradigm from conventional broad-spectrum cytotoxic compounds to molecular
agents selective for specific targets. Anticancer drugs, molecular inhibitors, and nucleic acids have all

AN

shown to be effective mostly in monogenic diseases, but these modalities are challenged in the face of

M

cellular heterogeneity and adaptive resistance in cancer [5, 7, 9]. In many aggressive heterogeneous
cancers with adaptive resistance, strategies to target individual signaling pathways have failed to block

ED

abnormal proliferation and metastasis due to cellular plasticity enabling the cells to restore the activities

PT

of interfered pathways or deployment of alternative pathways for vital cellular activities [6]. To this
end, a new strategy employing combinational therapy, which comprises of co-delivery of multiple

CE

types of therapeutic agents via nanoparticulate carriers, is emerging. This strategy guides the joint

AC

payload through multi-dimensional transport routes in cells [10] and it is intended to trigger synergistic
effect(s) via complementary pathways, generating a greater effect than the sum of the constituent
components [11-15] (Figure 1). Synergistic combination of agents may further overcome possible
toxicities associated with clinical doses of individual drugs by allowing lower doses of individual
components to be employed [16-18]. In an ideal combination therapy, each component could display
independent pharmacodynamics, with minimal overlapping of the toxicity spectra, or display joint
pharmacokinetics profile if the desired outcomes are optimized in this way.
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Multidrug cocktails were the earliest combinations explored and, with the advent of nanocarriers in the 25 to 250 nm range, it is becoming convenient to encapsulate drug cocktails into a single
carrier
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Figure 1. Combinational nucleic acid delivery. Different types of carriers and therapeutic agents can

ED

form nano-sized formulations with therapeutic agents that enter the cell, and release their payload to

PT

influence specific pathways that may preferentially result in synergistic anti-tumor activities.

and several of these formulations were approved for clinical applications [19]. Combination of nucleic

CE

acids and anti-cancer drugs has recently emerged to specifically tackle the critical issue of multidrug

AC

resistance (MDR) [20, 21]. While other reviews focused on the latter theme [22, 23], we specifically
focus on the delivery of nucleic acid combinations (D-NAC) in this manuscript. Nano-carriers are an
integral part of this approach, since they can provide physiological protection of the payload (especially
critical for highly-sensitive nucleic acids), reduce systemic toxicity (by delivering the cargo to target
organ/tissue/cells),

and

enhance

bio-availability

after

systemic

administration.

By

controlling

intracellular trafficking of the payload (Figure 2), nanocarriers could improve efficacy of the agents by
delivering their cargo to the appropriate sub-cellular compartment. Nano-carriers can address one of the
fundamental challenges of combination therapy, namely the variable pharmacokinetics and bio-
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distribution of inherently different constituent agents [23, 24]. Therefore, it is crucial to understand
nano-carrier design in D-NAC and the emerging molecular opportunities to translate combinational
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T

therapy.

Figure 2. Intracellular trafficking of nucleic acid therapeutics. The nucleic acids could be loaded and
delivered with the same carrier to couple the pharmacokinetics of multiple agents (top left) or delivered
via different carriers to optimize delivery efficiency or timing for each agent (top right). Depending on
the functionality of the nucleic acid, cytoplasmic or nuclear delivery might be needed.
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2.

Rationale for Delivery of Nucleic Acid Combinations (D-NAC) in Cancer Gene Therapy
Therapy via D-NAC ideally targets multiple pathways associated with signaling networks such

as phosphatidylinositol 3-kinase (PI3K)/Akt, nuclear factor κB (NF-κB), Janus-activated kinase/signal
transducer and activator of transcription (JAK/STAT), and various activators of transcription,
apoptosis, growth/invasion and angiogenesis [25]. Apoptosis inhibition by over-expression of anti-

IP

T

apoptotic mediators including Mcl-1, Bcl-2, and survivin, and mutation in drug targets, such as MEK,

CR

Epidermal Growth Factor Receptor (EGFR) and BCR-Abl, are associated with cellular resistance
against conventional therapeutics [13, 26-30]. Heterogeneity in the malignant cell populations and a

US

complex web of signaling networks continuously limit the outcome of one dimensional therapies.
Three major approaches to combinational therapy include inhibition of specific targets by multiple

AN

strategies, abolishing multiple components in a given pathway (to better eradicate a given pathway),

M

and interfering with multiple mechanisms in tumor growth and metastasis [12]. The overall goal is to
generate a better efficacy with minimal side effect by delivering multiple types of therapeutic agents

ED

[12, 22, 23]. The combined drug actions could be, preferentially, synergistic, additive, or based on

PT

coalition [31], where individual agents are inactive, but show efficacy in combination [32, 33].
Effective pairs of agents could be identified by exploring mechanistic insights from the

CE

literature or high-throughput screening without introducing a bias in the selection process (Figure 3)

AC

[34-36]. A suitable combination is expected to generate a synergistic effect, but combinations can often
exhibit an additive or even antagonistic effect due to variation in protein expression in malignant cells
[9, 37]. With over-expressed mediators, the higher the available target levels, the greater the effects via
synergy and usually the lower the synergistic side effects. In many cases, inter-connectivity of
signaling pathways does not allow sufficient effect by simply switching to alternate proteins, and/or
functional mutations [18, 38]. Combination therapy that address different mechanisms may overcome
this limitation by simultaneously blocking a greater number of pathways. One can envision co-delivery
of combination drugs in a single carrier, delivery in a mixture of distinct (separate) carriers, or

ACCEPTED MANUSCRIPT
subsequent delivery of an agent following delivery of another agent in a carrier [23, 39]. The
pharmacodynamics of the individual agents are likely to play a key role in the choice of the delivery
strategy.
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Figure 3. Screening of an siRNA library to identify synergistic pairs of effective siRNAs. A library of
446 siRNAs against apoptosis-related proteins (Dharmacon siGENOME Human Apoptosis siRNA
library) was screened with MDA-435 cells (a poorly differentiated breast tumor line expressing both
epithelial and melanocytic markers) in the absence and presence of kinesin spindle protein (KSP)
siRNA (top graph). A low concentration (14 nM) of KSP siRNA was chosen to minimize its effects
on its own. The presence of an apoptotis-related siRNA could (i) abolish (KSP induced growth
inhibition < -20%; i.e., antagonistic effects), (ii) not influence (KSP induced growth inhibition between
-20% and 20%), or (iii) enhance (KSP induced growth inhibition > 40%; additive or synergistic effect)

ACCEPTED MANUSCRIPT
the effect of the KSP siRNA (bottom graph). The latter class of siRNA combinations are desirable for
complementary enhancement of therapeutic efficacy (unpublished).

3.

Vehicles and Nucleic Acids in D-NAC
Both viral vectors and non-viral carriers are explored in D-NAC [30, 40, 41], where both

T

approaches displayed significant anti-cancer effects compared to corresponding monotherapies. In

IP

combination therapies, viruses are specifically utilized to induce protein expression, specifically in

CR

immunotherapy (cancer vaccines), and the combination of suicide gene therapy and cancer vaccines
has been shown to be an effective synergistic pair to induce anti-tumor response in both in vitro and in

toxicity, limited cargo capacity and manufacturing

AN

limitations such as insertional mutagenesis,

US

vivo models [40, 42, 43]. However, it is difficult to explore viruses in clinical settings due to several

challenges. Safety issues especially have propelled the non-viral delivery to clinical stage, which are

M

more convenient for RNA-based agents as well. Cationic lipids and natural/synthetic polymers are

ED

utilized to achieve synergistic effects among therapeutic agents [10, 44-50]. The strategies for
combination delivery using non-viral carriers include co-delivery (therapeutics are encapsulated into a

PT

single carrier), mixed delivery (individual therapeutics are encapsulated in different carriers) and

CE

subsequent delivery (one therapeutic is encapsulated whereas the other one is free) [23, 39]. While the
co-delivery is usually performed when nucleic acids payloads display similar characteristics (e.g., a

AC

combination of different plasmids, or a cocktail of siRNAs targeting different proteins), mixed and
subsequent delivery could be used to deliver different types of nucleic acids and even a combination of
nucleic acids and small molecule drugs. Facile and versatile chemistry is the promising aspect of nonviral carriers for combinational cancer therapy (see Figure 4 for representative carriers). Due to the
lipid bilayer envelope and an aqueous phase at the core, liposomes could potentially encapsulate
different

nucleic

acids,

as

well

as

small molecule

drugs

simultaneously.

A

liposome-like

multicomponent system, stable nucleic acid-lipid particles (SNALPs, with a solid lipid core), has relied

ACCEPTED MANUSCRIPT
on the concept of ‘combinational’ delivery system; SNALP supramolecules incorporate different
building blocks based on the needs of delivery. While the primary structure of the SNALP is based on
lipid bilayer, novel cationic lipids with increased fusogenic properties have been introduced that are
capable of binding to nucleic acids via interionic interactions [51]. In 2005, Heyes et al. reported a
series of new cationic lipids with different saturation degrees, among which 1,2-dilinoleyloxy-N,N-

IP

T

dimethyl-3-aminopropane (DLinDMA) with two double bonds per alkyl chain showed significant

CR

efficiency in cellular uptake after incorporation into SNALP structure [52]. The same cationic lipid was
later improved to create DLin-KC2-DMA, which showed in vivo activity at siRNA doses as low as

US

0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates [53]. The other components of SNALPs
could include PEG (to create stealth properties and enhanced permeation and retention effect), cell

AC

CE

PT

ED

M

AN

penetrating peptides (to enhance cellular internalization), and monoclonal antibodies (for active
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targeting). Cationic lipids, liposomes, and peptides have been additionally used for nucleic acid
delivery; however, SNALP is proposed to combine their capabilities for a more efficient and reliable
delivery.

Cationic Lipids and Lipoplexes in Combinational Delivery

IP

3.1.

T

Figure 4. Chemical structures of the main lipids, polymers and their derivatives utilized in the D-NAC.

acids

to

host

cells.
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AN

Oligofectamine®, DharmaFECT®, etc.) and DOTAP:cholesterol based cationic liposomes are most

AC

Hyaluronic acid grafted polyethylenimine
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effective among lipid-based delivery agents [41, 54-56]. These lipofection reagents were explored to
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deliver a wide array of nucleic acid combinations based on both RNA and DNA (Figure 4). With nonionic formulations, the aqueous core makes it possible to entrap multiple nucleic acids at desired ratios;
however, unlike small molecule drugs, nucleic acids cannot penetrate the lipid membrane and the
liposome needs to be destabilized in order to release its payload. DOTAP/cholesterol liposomes were
employed for successful co-expression of functionally synergistic tumor suppressor genes, FUS1/p53

IP

T

in human non-small cell lung carcinoma (NSCLC) cells and its xenograft model [57]. The commercial

CR

reagent Lipofectamine® 2000 (not suitable for animal models) has been most commonly used in
combinational delivery, though other carriers (Table 1) have also shown effective performance in in

US

vitro and in vivo models. Cationic charge density, hydrophobic tail conformation and the spacer length
could be optimized for co-entrapment and co-delivery, but chemically-modified lipids especially with

AN

cationic functionalities (e.g., polyethyleneimine (PEI), polyamidoamine (PAMAM) and polylysine

M

(PLL) derivatives) are particularly attractive to tailor the liposomes for nucleic acid payloads. [44, 58].
Being localized at the inner and outer aqueous interfaces of liposomes, the cationic moieties could act

ED

as binding sites for anionic nucleic acids through electrostatic interactions [44, 45]. The cationic groups

PT

can also provide a spacer for anchoring specific motifs and binding ligands to generate cell specificity
for active targeting. With liposomes that bear nucleic acids on the outside surface, displacement of

CE

nucleic acids with other anionic species such as heparin sulfate [59] is always a concern, which results

AC

in premature release of the payload, as well as its rapid digestion of nucleic acids in serum. While
maintaining proper balance of active agents after loading multiple nucleic acids in carriers is always a
concern in combinational delivery, having a secondary nucleic acid may lead to improved
pharmaceutical effects; DNA supplementation in short interfering RNA (siRNA) formulations of
liposomes were noted to enhance the silencing activity of siRNA, not due to gross morphological
changes in liposomes but possibly due to altered dissociation/release of the nucleic acids from the
lipoplexes [60]. A similar observation was also made with polyplexes [61], where the presence of a
‘helper polyanion’, a plasmid DNA in this case, was able to significantly improve the silencing activity

ACCEPTED MANUSCRIPT
of polyplex formulations. It must be pointed out that the structural features of the polyplexes were
vastly different after the addition of helper polyanion DNA in this study (unlike the lipoplexes
investigated above), and that a relatively ineffective carrier (PLL) was used as the nucleic acid carrier.

3.2

Cationic Polymers and Polyplexes in Combinational Delivery

T

Cationic polymers, the leading materials in D-NAC, can be configured into multiple forms,

IP

including micelles, hollow polymersomes and homogenous nanoparticle (NP) polyplexes [49, 62, 63].

CR

They were broadly effective in several type of cancers (Table 1) after being employed in their native
Low molecular weight PEI

US

form or after derivatization with functional moieties (Figure 4) [15, 30].

(LMW; <2 kDa) was derivatized with a broad range of hydrophilic and hydrophobic moieties to

AN

transform them into effective carriers [46, 64]. Hydrophobic modification of LMW PEIs with
aliphatic/aromatic moieties imparts lipophilicity to already existing buffering capacity. Synergism

M

between these features enables improved self-assembly during complexation with nucleic acids while
binding

to

hydrophobic

domains

ED

enhancing

of plasma

membrane

that

ultimately

enhances

PT

internalization [65, 66]. LMW PEIs grafted with aliphatic lipids (C8 to C18) generate relatively nontoxic PEI derivatives, and even small hydrophobes (C3) appear to be functional for nucleic acid

CE

delivery [67]. As with single agents, these polymeric derivatives displayed superior delivery of siRNA

AC

cocktails with a single carrier and enabled down-regulation of target genes without interfering with
each other [30, 68]. Chemical modification of higher MW PEI (10 kDa) with the natural polyanion
hyaluronic acid (HA) was proposed to generate more compatible derivative, since it can neutralize
excess cationic charge density to decrease cellular cytotoxicity, while still preserving siRNA
encapsulation capacity [69]. PEI-HA was utilized to formulate a dual-functional (CD44/EGFRtargeting) nano-carrier for systemic delivery of p53- and miR-125b expressing plasmid in a mouse
model of lung cancer [70]. Chitosan (CS) is another natural cationic polymer extensively studied as an
alternative of PEI due to

its

perceived

biocompatibility.

Chitosan derivatives, galactosylated

ACCEPTED MANUSCRIPT
poly(ethylene glycol)-chitosan-graft-spemine (GPCS) copolymer and thiolated chitosan (tCS), are
typical CS derivatives employed in D-NAC [14, 15]. Here GPCS was utilized to deliver two different
tumor suppressor genes to hepatocellular carcinoma and tCS was used to deliver poly(siRNA) to
prostate cancer cells. In both approaches, CS derivatives were able to generate significant anti-cancer
activity.

IP

T

Rather than constructing polymeric conjugates for D-NAC, a simpler approach to designing

CR

multifunctional particles is to formulate the particles with multiple polycationic species, i.e., blending
(Figure 5). The polycations usually act to neutralize the anionic charges of nucleic acids along with

US

forming polyion bridges among the NA. Polymer-polymer interactions may further stabilize the formed
polyplex formulations. Along with anionic nucleic acids, one can incorporate other anionic species

AN

(e.g., HA) in polyelectrolyte complexes, or coat the already formed particles with polycationic species.

M

In the latter case, functional ligands (e.g., specific cell-targeting agents or anti-fouling agents) could be

AC
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incorporated into the surface coating.
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Figure 5. Schematics of NP formulation through coating and additive processes. Polyplexes formulated
using cationic polymer and a mixture of polyanions (e.g., HA and nucleic acid) leads to additive

US

nanocomplexes, while treating of polymer/nucleic acid complexes with an additional polyion leads to
coated nanocomplexes. While additive polyplexes are expected to display enhanced dissociation,

AN

surface coating optimizes interactions with serum components and membrane/cellular surfaces [65,

Nucleic Acids in Combinational Delivery

ED

3.3

M

71]. Surface coating procedure can be repeated several times for Layer-by-Layer (LbL) coated NPs.

Different strategies could be used to simultaneously deliver multiple nucleic acids based on the

PT

design of nucleic acids (Figure 6). It is challenging to formulate different nucleic acids into a single

CE

carrier due to variations in ionic charge density, size, and stiffness of the constituent molecules, and
this becomes more significant while employing smaller molecules like siRNA [15, 72]. This approach

AC

to RNA interference (RNAi) technology has quickly become a dominant player in preclinical and
clinical studies based on its synthetic mediator, siRNA. However, small size, low charge density and
high chain stiffness limits siRNA’s complexation ability with the carriers. To resolve these challenges
and to protect the nucleic acid against early degradation in serum, many studies have reported using
either chemically modified or encoded (e.g., co-expressing plasmid construct) siRNAs [14, 15].
Chemical modification of siRNA has been developed to design multimeric and polymeric siRNAs with
higher MW and higher electronegative charges density (Figure 7). Insertion of labile bonds among
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multimeric species is desirable to exploit intracellular reductive environment, such as end-capping
siRNAs with thiol groups produce multimeric siRNA species held together with labile disulfides [14,
72, 73]. The multimeric siRNAs may form more stable complexes with cationic carriers, before
undergoing reductive cleavage to release siRNAs. The initially released species will presumably be a

AC

CE

PT

ED

M

AN

US

CR

IP

T

mixture of individual siRNAs as well as oligomers, which may further breakdown intracellularly.
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Figure 6. Schematic representation of possible nucleic acid combinations. (A) Therapeutic protein
combination. (B) Therapeutic protein and shRNA combination. (C) Therapeutic protein and miRNA
combination. (D) Therapeutic protein and siRNA combination. (E) shRNA combination. (F) shRNA
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and miRNA combination. (G) shRNA and siRNA combination. (H) siRNA combination composed of
individual siRNAs or multimeric siRNAs (I) siRNA and miRNA combination. In the case of pDNA
driven expression systems (proteins, shRNA and miRNA), either independent expression systems or
co-expression systems could be used. In the case of miRNA delivery, it is possible to deliver miRNA

poly-siRNA
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CR

HS

IP
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or anti-miRNA reagents to exert a desired therapeutic effect.

siRNA-SH

US

HS

Dual-poly-siRNA

AN

Figure 7. Schematic for the synthesis of polymerized siRNAs, composed of either unitary siRNA

M

blocks, or dual siRNA blocks (adopted from reference [14]).

ED

Formulating a combination with DNA and siRNA is challenging due to differences in physical
and electronic properties (e.g., charge distributions, dipole moments, polarizabilities and proton

PT

affinities), but a co-expression system for a therapeutic gene and a short hairpin RNA (shRNA) can be

CE

a convenient solution [13, 57]. Viral vectors loaded with multiple genetic material have been initially
designed especially in tumor vaccination [40, 42, 43], for example with immune-stimulatory molecules

AC

for anti-cancer immunity. In some studies, DNA-intercalating feature of anti-cancer drugs (e.g.,
doxorubicin) was exploited for encapsulating and delivering complementary agents [74, 75]. These
complexes are formulated by allowing DOX intercalation into double-stranded 5’-GC-3’ or 5’-CG-3’
base pairs, which are then condensed with cationic polymers and dendrimers [76]. This strategy offers
better control on the efficiency of loading and delivery of payload.

4.

Specific Nucleic Acid Combinations for Cancer Therapy

ACCEPTED MANUSCRIPT
The innate resistance of unresponsive tumors is usually attributed to tumor heterogeneity. In
2015, Sottoriva et al. proposed a ‘Big Bang’ model of tumor initiation that suggests after initial
oncogenic mutation, future generations acquire further mutations, which are present in discrete
populations of cells, leading to spatial heterogeneity [77]. A more diverse pattern has been reported in
other types of cancers. Amir et al. studied two human acute lymphoblastic leukemia samples with
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viSNE technology, and reported a large, irregular population of cells that were more different than
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similar [78]. The sub-population with intrinsic resistance to therapeutic assault would survive and
outgrow other cells due to the selection pressure; this will promote relapse, which results in abundance

US

of originally minor cells [79]. This “Darwinian clone selection” has been well-documented in different
types of cancer in response to a variety of molecularly-targeted drugs [80]. On the other hand, plasticity
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of cancer cells that enables adaptation to molecularly targeted drugs could explain the acquired

M

resistance. In addition to point mutations, availability of a variety of pathways leading to enhanced
proliferation and survival could be responsible for the intracellular adjustments required. Our
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understanding of intracellular signaling cascade is evolving, and new “cross-talk” between different

PT

pathways and previously seemingly unrelated proteins are reported on a regular basis.
Latest reports have led to elucidation of a key role of JAK/STAT signaling pathway in

CE

development, proliferation, differentiation, and survival of cancer cells [81]. JAK is associated with a
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variety of transmembrane receptor families [82], and propagates signaling to cytoplasmic proteins such
as the STAT proteins. Over-activation of JAK family members has been implicated in tumorigenesis
[83], and persistent activation of STAT3, and to a lesser extent STAT5, has been shown to increase
proliferation, survival, angiogenesis and metastasis in a variety of human cancers [84, 85]. Similarly,
PI3K/Akt pathway regulates proliferation, survival, motility and morphology, and have been associated
with cancer pathogenesis [86]. Studies indicate that receptor tyrosine kinases (RTKs), including growth
factor receptors, play a major role in activation of this signaling pathway [87]. PI3K/AKT pathway is
one of the most commonly disrupted pathways in human breast cancer, and the PI3K-dependent
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activation of the serine/threonine kinase AKT and its downstream effectors are some of key factors in
cell survival mechanisms. In cancers that are sensitive to RTK inhibitors, PI3K signaling could be
initially lost; however, other routes soon emerge to activate the PI3K signaling [88, 89]. Binding of
growth factors to cell surface receptors could also activate Ras/Raf/MEK/ERK pathway. Mutations in
KRAS, BRAF, MEK1 or MEK2 result in growth factor-independent ERK1 and ERK2 activation,
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which results in enhanced cell proliferation and survival [90]. Activated ERK also translocates to the

mitogens and are up-regulated in several human tumors [91].

CR

nucleus to activate transcription factors, including FOS. The ERK1 and ERK2 MAPKs are activated by

US

However, the boundaries between these categorized pathways are fading with each report on a
newly identified link among the major proteins in these pathways. For instance, the activation of
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tyrosine kinase HER2 located on breast cancer cell membrane is shown to trigger phosphorylation of

M

RAF and Ras that regulates Bcl-2 family proteins [92]. MUC1 protein interacts with several
cytoplasmic proteins, as well as Ras-MEK-ERK2 signaling pathway [93] and STAT3 (via Src signaling

ED

pathway) [94]. Activation of mTOR downstream effectors by p38 MAPK pathway [95], the effect of
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STAT3 activation on Ras and PI3K/Akt pathway [96], and JAK on PI3K and ERK pathways [97, 98]
are other examples of these inter-pathway cross-talks. Studies even indicate that this crosstalk

CE

contributes to a deregulation of PI3K signaling that can lead to tumorigenesis [99]. This could partially
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explain the preclinical data indicating a failure to induce apoptosis despite effective inhibition of PI3K Akt components [100, 101], which may suggest that a single inhibitor might not create a significant
response even in sensitive cells.
The cellular heterogeneity implies that blocking one mechanism of survival would not be
effective against the whole population. A subpopulation that does not rely on the targeted mechanism
will be selected in this case. Even the cells that do respond could potentially adjust and rely on an
alternative signaling pathway. Therefore, simultaneous targeting of multiple carefully selected proteins
seems inevitable,

and

novel drug carriers for co-delivery of multiple agents, with different
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pharmacokinetics and pharmocodynamics features have to be designed. Proper combination of agents
is important to minimize antagonistic effects [9, 102, 103]. Various combinations of DNA and RNA
molecules have been explored to achieve synergistic effect(s) at the molecular level (Table 1). While
synergistic agents can be delivered using either a single or mixed carriers, co-delivery through a single
carrier is likely to be preferred due to its convenience, and simultaneous delivery of the components of
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the combinatorial therapy to the site of action. A single carrier has the potential to deliver the payloads

CR

at the proper balance to a target site at the same time, if desirable, and generate cumulative activities, if
the carrier/payload is stable enough to prevent premature release of any of the payload. Among the

US

nucleic acid combinations, siRNAs are gaining upper hand to complement the action of a DNA-based

Combinational delivery to up-regulate suppressor genes

M

4.1

AN

expression system [104].

Mitochondria, the powerhouse for different cellular activities, is an effective therapeutic target

ED

since its activity directly impacts tumorigenesis [105-108]. Shin et. al. delivered an expression system

using

galactosylated

PT

for two mitochondria targeting genes, LETM1 and CTMP, which were linked together by 2A peptide
poly(ethylene

glycol)-chitosan-graft-spermine

(GPCS)

in

hepatocellular

CE

carcinoma (HCC) model [15]. LETM1, a mitochondrial inner membrane protein, and CTMP, a binding
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partner of Akt, are responsible for maintaining the proper morphology of mitochondria, but their overexpression was reported to generate mitochondrial defects that induce cell death [108-111]. The
elevated LETM1-2A-CTMP substantially modulated mitochondrial morphology such as swelling and
loss of cristae via optic atrophy-1 (OPA1) cleavage, which was typically observed in mitochondria due
to LETM1 expression [112]. The mitochondria displayed enhanced release of Bax (a pro-apoptotic
protein that induces cell death) and cytochrome C (that binds to Apaf-1 and activates caspase-3dependent apoptosis) after LETM1-2A-CTMP delivery. The therapeutic action was driven by the
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synergistic actions of LETM1 and CTMP overexpression, which was facilitated by self-cleaving 2A
peptide sequence [113].
Similarly, LKB1 (liver kinase B1), FUS1 and p53, well-established tumor suppressors, were
incorporated into a co-expression plasmid and delivered via different carriers [54, 57]. Each gene
induces apoptosis through a different mechanism; FUS1 expression is associated with silencing of
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protein tyrosine kinases, which induces mitogenic signaling through mTOR pathway [114]. LKB1 is a
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tumor-suppressor gene associated with p21/p53 gene expression, stability and activity [115, 116]. A
synergistic effect based on induction of apoptosis and cell cycle arrest was observed in NSCLC model,
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leading to prolonged survival of tumor-bearing mice after delivery of LKB1/FUS1 co-expression
plasmid with cationic liposomes (DOTAP/cholesterol) [54]. Compared to individual delivery, the
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delivery of co-expression plasmid substantially up-regulated the expression of p-p53, p-aMPK and

M

silenced the expression of p-mTOR in a synergistic manner. FUS1 was also employed to construct a
co-expression plasmid with p53 gene [57]. p53 is frequently mutated or deleted in human cancers and
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exogenous overexpression of wild-type p53 gene has proved effective in tumor growth inhibition [117].
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Successful delivery of FUS1/p53 co-expression plasmid to NSCLC model using DOTAP/cholesterol
NPs generated synergistic effect in suppressing cell growth via inducing apoptosis in in vitro and in
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vivo models [57]. The synergism between FUS1 and p53 was reported to be due to FUS1-mediated
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silencing of murine double minute-2 (MDM2), which is one of the prominent negative regulator of p53
protein [118]. The silencing of MDM2 enhanced p53 accumulation, up-regulated the expression of proapoptotic gene Apaf-1, protease-activating factor-1 [119] and ultimately induced apoptosis.

4.2

Combinational delivery to simultaneously up- or down-regulate target genes
Co-delivery of DNA and siRNA pairs is a sophisticated approach since it can simultaneously

intervene in two separate pathways protein [13, 41, 70, 120]. However, it is challenging to co-deliver
agents of different electro-physical properties. Pan et. al. reported an additive effect of co-expressing a
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STAT3-specific shRNA and LKB1 [41] on inhibition of ovarian cancer growth in vitro and in vivo,
which were revealed in a multitude of assays including proliferation, colony formation, cell cycle
distribution, apoptosis, migration, and tumor growth inhibition. LKB1 expression was reported to
inhibit STAT3 activation, which is associated with different cellular activities [121, 122], so that it
acted in concert with direct inhibition of STAT3 with shRNA in this case. Other effects of co-

of

cyclic

D1,

survivin

and

Bcl-2.

Furthermore,

STAT3/LKB1

intervention

CR

down-regulation
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expressing STAT3 shRNA and LKB1 plasmid was up-regulation of p21 and p-p53 expression, and

synergistically suppressed SKOV3 cell migration and invasion, which was due to reduced MMP-2 and

US

MMP-9 expression associated with extracellular matrix turnover [41]. Synergistic effect of STAT3
shRNA with Gene Associated with Retinoid-IFN-induced Mortality 19 (GRIM-19) was also reported
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to inhibit thyroid and prostate tumor growth in both in vitro and in vivo models [123, 124]. GRIM-19

M

is a potential tumor suppressor, whose over-expression inhibits cell proliferation and induces apoptosis
in human prostate, breast and gastric cancer, and renal cell carcinoma [125-127]. GRIM-19 could also
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inhibit STAT3 expression by exclusive interaction with transcriptional activating domain of STAT3

PT

and inhibiting auto-regulatory STAT3 driven transcriptional activation [128]. The dual expression
plasmid of STAT3 shRNA and GRIM-19 showed significant suppression of cell proliferation,

CE

migration and invasion in in vitro and in vivo models of thyroid carcinoma [123]. In a similar study, co-
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expression of STAT3 shRNA and GRIM-19 synergistically suppressed prostate tumor growth and
metastases when compared with individual treatment with either agent [124]. The combination therapy
completely extinguished the activity of MMP-2 and vascular endothelial growth factor (VEGF), two
key players in metastasis. A shRNA against survivin, a member of inhibitor of apoptosis protein (IAP)
family and key regulator of apoptosis, was also delivered with GRIM-19 [89], with a synergistic effect
on proliferation of laryngeal cancer (Hep-2) cells [120]. The effect was promising in both in vitro and
in vivo models compared to corresponding mono-therapies, which indicates an association between
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survivin and GRIM-19 in cellular signaling. The expression of GRIM-19 could have possibly inhibited
the downstream STAT-3 gene as well.
Combination therapy has been also explored in malignant glioblastoma, the most common
tumor in central nervous system. Han et. al. reported construction of a co-expression plasmid of EGFR
shRNA and PTEN, and investigated their synergistic in suppressing cell proliferation, cell cycle and
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invasion in U251 glioma cells in vitro and inhibition of subcutaneous U251 glioma tumors in nude
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mice [13]. Delivery of the plasmid substantially down-regulated the EGFR expression and up-regulated
PTEN expression, while the expression levels of p-AKT, PCNA, Bcl-2, CyclinD1, MMP-2 and MMP-

expression

activates

US

9 were dramatically decreased, leading to diminished AKT activity. In glioblastoma cells, EGFR
specific downstream intracellular signaling pathways

that lead

to

PI3K
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phosphorylation and activation of AKT, while PI3K is negatively regulated by PTEN [129, 130]. These

M

findings suggest that the retarding glioblastoma growth was the combined effect of reduced cell
proliferation and apoptosis induction. Along the same lines, shRNA targeting Akt1 (shAkt1) and

ED

cDNA of Programmed Cell Death Protein 4 (Pdcd4) were inserted into a dual expression vector, which

PT

was delivered into lungs with a sorbitol diacrylate-PEI carrier after aerosolization; a synergistic
antitumor effect was evident on the lung tumors with this combination of agents [131].

CE

Combination of siRNA and DNA delivery using a single carrier is beginning to be explored.
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Non-viral carriers that are typically used for siRNA delivery are usually capable of forming complexes
with plasmid DNA as well. While the site of action for siRNA is cytoplasm, getting the DNA to
nucleus is one of the major challenges. “Naked” DNA does not easily diffuse into the nuclear envelope;
however,

interaction

with

cytoplasmic

proteins

could

trigger

importin

signaling

for

nuclear

localization. Incorporating peptides or specific ligands are among approaches to enhance nuclear
delivery of DNA [132]. One of the approaches reported for co-delivery of DNA and siRNA is
formation of micelle-like NPs based on interionic interaction with the nucleic acids. This type of
delivery system generally follows the typical micellar core/shell structure, with hydrophobically
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modified polyamines forming the core after interaction of the polyamine and siRNA (which neutralizes
the ionic charge and increases the hydrophobicity), and a hydrophilic moiety [133]. NPs formed by
gold/PAMAM nucleic acid complexes showed efficient simultaneous delivery of siRNA and DNA to
cytoplasm and nucleus of brain cancer cells, respectively (confirmed by transmission electron
microscopy), and superior silencing efficiency compared to Lipofectamine® 2000 [134]. Similarly, a
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pDNA and siRNA were condensed with branched PEI and deposited onto poly(lactide-co-glycolic
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acid) (PLGA) NPs for delivery to human mesenchymal stem cells (not cancer therapy) [135]. Lu et al.
recently reported a derivative of branched PEI (grafted with arginine-rich oligopeptide) for co-delivery
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of siRNA and DNA that increased the transfection efficiency 20-folds, and silencing efficiency 2-folds
compared to individual delivery of DNA and siRNA, respectively [136]. The exact mechanism of the
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increased efficiency was unclear. In 2016, Kim et al. reported simultaneous delivery of siRNA against

M

Src Homology Region 2 Domain-containing Tyrosine Phosphatase-1 (SHP-1) and plasmid DNA
expressing VEGF using a deoxycholic acid-modified PEI to cardiomyocytes, as a strategy to reduce

manuscript has also reported incorporating anionic poly-γ-glutamic acid (γ-PGA)

PT

deliveries. A recent

ED

apoptosis and enhance vascularization [137], which showed synergistic effect over individual

4.3
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cell line [138].
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in PEI/nucleic acid complexes, with high transfection and silencing efficiencies in a human hepatoma

Combinational delivery to silence the over-expressed genes
Delivery of siRNA combinations has been actively explored in combinational therapy to

simultaneously down-regulate over-expressed genes associated with tumor growth and metastasis.
Several distinct steps involved in tumor formation and growth, such as angiogenesis, abnormal
apoptotic process, drug resistance and immune-modulation, have been modulated by this approach.

4.3.1

Inhibition of Angiogenesis
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Angiogenesis is a fundamental requirement as tumors transform from benign to metastasizing
state, characterized by extensive blood vessel formation, and it involves migration, proliferation and
differentiation of cells responsible for vascular assembly. VEGF is a potent angiogenic factor targeted
in cancer therapy since it stimulates rapid formation of new, leaky vasculature, tumor cell migration,
while decreasing response to hormonal/chemotherapy [139, 140]. Humanized monoclonal antibody
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“bevacizumab” against VEGF has been successfully used in many clinical cases individually, and as
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part of combination therapies [141, 142]. Its delivery has been explored for synergistic activity with
antibodies against other targets, such as epidermal growth factor receptor 2 (HER-2; a humanized

US

HER-2 antibody “trastuzumab” is approved for treatment of HER-2 positive breast cancers [143, 144]).
This combination shows substantial effect in suppressing growth and invasiveness in different cancers
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[145, 146]. A synergistic effect of blocking HER-2 and VEGF expression with siRNA combinations

M

was reported in a breast cancer model [145]. A multitude of effects on tumor cells was noted, including

ED

changes in cell morphology, suppression of migration and cell adhesion to ECM, and some of these
effect were due to alterations in other intracellular regulators such as Pak1, PI3K and HIF1. These

PT

findings are consistent with the therapeutic outcome of VEGF/HER-2 antibody combination in clinical
studies [144, 147], so that siRNA-based combinations appear to mimic the respective antibody therapy.
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An HER-2/VEGF siRNA combination was also employed in human gastric carcinoma therapy with
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similar synergistic results [146]. A substantial knockdown of VEGF and HER-2 mRNAs was observed,
leading to inhibiting cell proliferation, migration and inducing apoptosis.

4.3.2

Inhibition of cell proliferation
The RNAi technology that targets the molecular mediators responsible for abnormally regulated

cell cycle is another fruitful approach in combinational therapy. KSP, a member of kinesin superfamily
of microtubule-based motors, is involved in centrosome separation, bipolar assembly and maintenance
during mitosis. A siRNA targeting KSP was explored to synergize with a VEGF siRNA in treatment of
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different cancers [148]. The delivery of KSP/VEGF siRNA combination to Hep3B cells showed
significant down-regulation of the intended target KSP, as well as other important targets regulating
cell cycle regulators (e.g., Cyclin D1) and anti-apoptotic proteins (e.g., Bcl-2 and survivin), suggested a
highly integrated response to VEGF silencing. In a recent study, we also reported successful delivery of
siRNA combinations against cell-cycle regulators TTK protein kinase and cell dividing cycle protein
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20 (CDC20) and anti-apoptotic survivin in a triple negative breast cancer model (MDA-MB-231 cells)

CR

using cationic lipopolymers [68]. These siRNA combinations primarily silenced the target gene at the

4.3.3

US

mRNA level and resulted in an anti-proliferation activity that was synergistic in nature.

Induction of apoptosis
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Over-expression of anti-apoptotic family of proteins (e.g., Bcl-2, Mcl-1, XIAP) in many

M

malignances are reported to contribute to increased cell lifespan [26, 149] in addition to drug
resistance. siRNAs targeting anti-apoptotic proteins Bcl-2 and survivin show effective synergism with
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VEGF siRNAs in many cancer [14, 150]. Multimeric siRNAs were constructed using labile -S-S-

PT

bonding and they displayed better activity with anti-apoptotic Bcl-2 [14] and other targets, especially
VEGF [71,72, [14, 72, 73, 150, 151]. Intracellular reductive cleavage of -S-S- bonding of multimeric
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siRNAs promptly releases constituent siRNA units, which triggers the silencing process of targeted
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genes, and generates synergistic effect in tumor suppression. The combinational delivery was highly
effective at mRNA silencing and significant anti-cancer activities was observed, which was higher than
mono-therapy [14, 73]. Multimeric VEGF and NET-1 siRNAs were reported for liver cancer treatment
with synergistic outcomes in several functional assays [151]. siRNA mediated silencing of NET-1
inhibits cell proliferation and induce cell apoptosis via down-regulation of cyclinD1 and Bcl-2
regulators. Delivering a multimeric siRNA bearing siRNAs against solely anti-apoptotic proteins (Bcl2 and survivin) resulted in higher anti-cancer efficacy than mono-therapies in treatment of bladder
cancer T24 cells [150]. In leukemia, several studies also explored combinational delivery of
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(monomeric) siRNA to enhance apoptosis; siRNAs against WT1/BCR-Abl (using TransMessenger® as
carrier) [152],

GRI1B/BCR-Abl (using DOTAP as carrier) [153] and c-RAF1/Bcl-2 (using

Oligofectamine® as carrier) [154] combinations were explored to inhibit un-controlled cell proliferation
and apoptosis induction (Figure 8). Combinational delivery typically resulted in higher efficacy in both
inhibiting proliferation and apoptosis induction, but the effects were not always synergistic or additive.
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Careful selection of targets was therefore necessary when complementary siRNAs were used in

CR

targeting transformed cells. While not all mediators are expected to act synergistically when they are
silenced with specific siRNAs, whether a carrier influences the obtained effect, via specific effects via

US

siRNA delivery and release kinetics or indirect effects on cellular physiology, is a critical issue, and
remains to be explored.
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Figure 8. Effects of combinational siRNA treatment in leukemic cells. The siRNAs indicated on the
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horizontal axis is added alone (squares representing the first siRNA, diamonds representing the second
siRNA) or in combination (circles). The cells used in these studies were K562 (a CML cell line), HL60 (an AML cell line) or primary CML cells obtained from patients. The decrease in proliferation
(right; as a percentage of control) and increase in apoptosis (left; fold change over non-treated cells)
were summarized after our analysis of the reported data. Note the generally beneficial effect of siRNA
combinations compared to treatment with individual siRNAs alone.

4.3.4

Reversal of MDR against drug therapy
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The siRNA combinations are often utilized to tackle MDR, which is usually acquired by cancer
cells after frequent exposure to less than the lethal doses of a drug, and/or by selective growth of the
sub-population already expressing MDR proteins. The fundamental mechanisms behind this type of
therapeutic failure are: (1) decreased influx and/or increased efflux of drugs by cell surface
transporters, (2) change in drug efficacy due to genotypic and phenotypic changes in cancer cells, (3)
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blockage of normal apoptosis, and (4) activation of detoxifying systems against the drug. With better

CR

recognition of molecular mechanisms involved in MDR, co-delivery of siRNA/drug combinations have
demonstrated significant impact to restore cellular sensitivity to drugs [23]. Nucleic acid therapy with

US

siRNAs combinations has been also pursued and, prominently, it has been performed by targeting the
efflux protein P-glycorpoetin (P-gp) and anti-apoptotic proteins [26, 30, 155], since over-expression of
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anti-apoptotic proteins (e.g. Bcl-2, Mcl-1) is a hallmark of increased cell survival and drug resistances

M

[26, 149]. Successful delivery of siRNA combinations against P-gp and Mcl-1 or survivin was shown
in a breast cancer model using cationic lipopolymers [30]. A higher efficacy of the combination therapy
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was observed relative to the mono-therapy [30]. A more comprehensive study by our group

PT

demonstrated a synergistic effect when siRNA combinations against anti-apoptotic proteins and kinases
were employed in doxorubicin-resistant breast cancer model [26]. This study indicated a significant

CE

synergistic effect for siRNAs targeting Mcl-1 and Ribosomal Protein S6 Kinase (RPS6KA5). While
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siRNA targeting RPS6KA5 had no significant impact on the viability of wild-type and resistant
versions of MDA-MB-435 cells, combinatorial delivery of siRNAs targeting Mcl-1 and RPS6KA5,
halted the tumor growth in a nude mice xenograft model. While tumor growth in the mice treated with
Mcl-1 siRNA alone was significantly slower as well, the efficacy of the combination therapy was
significantly higher. In contrast to different ‘classes’ of targets, combinational siRNA delivery solely
against anti-apoptotic proteins Bcl-2 and Mcl-1 was also effective in drug-resistant malignant pleural
mesothelioma [149].
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Solid tumors could develop resistance against EGFR therapy by activating alternative survival
mechanisms involving insulin-like growth factor-1 receptor (IGF-1R), which also belongs to receptor
tyrosine kinase family and contributes to aggressive tumor growth and poor prognosis [156-158]. As an
alternative to antibody combinations targeting IGF-IR and EGFR [159], combinational siRNA therapy
was shown to mediate dual silencing of EGFR and IGF-1R at mRNA and protein levels in a colorectal
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cancer model [55]. This combination inhibited phosphorylation of AKT and ERK1/2, which are known
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as the major components of downstream signaling pathways of EGFR and IGF-IR. It directly affected
cell proliferation and apoptosis, where the therapeutic intervention was substantially higher with

US

combinational delivery as compared to silencing of either target alone. Dual silencing EGFR and IGF1R using shRNA was also reported as an alternative approach [160]; enhanced apoptosis and increased
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cell sensitivity were observed to chemotherapy in the case of co-silencing, as compared to silencing

M

single targets in nasopharyngeal cancer cell lines.

Immunotherapy
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4.3.5
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An exciting therapeutic option in management of cancer is to rely on immune system to
eradicate the malignant cells. This will require to sensitize the immune components against malignant

CE

cells via antigen-dependent vaccination and/or cytokine mediated

stimulation.

A plasmid for
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simultaneous expression of IL-2, pro-IL-18 and IL-1b converting enzymes (ICE) were delivered using
gene gun to skin tissue surrounding tumor in a murine mammary adenocarcinoma model. This resulted
in higher anticancer activity as compared to individual genes as evident by increased level of bioactive
IL-18 and INF-γ induced [161]. The immune-modulatory genes granulocyte-macrophage colonystimulating factor (GC-CSF) and IL-2 were virally delivered in squamous cell cancer model in a
separate study [43], but GC-CSF showed suppressive effects in tumor growth with no obvious
advantage of combination therapy. The combination therapy has been explored for tumor metastasis by
employing suicide (e.g., herpes simplex virus thymidine kinase, HSV-tk) and IL-2 genes as a
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synergistic pair [40]. This combination has shown a substantial inhibition of metastasis of colon cancer
cells to liver and induced a systemic anti-tumoral immunity against parental tumors. A combination of
three genes (Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), HSV-tk and IL-2), was
subsequently explored in cancer treatment [42]. A substantial induction of long-term antitumor
immunity and survival of mice receiving GM-CSF/HSV-tk/mIL-2 treatment had been observed. The
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underlying synergism observed in this approach was due to amplified CTL activity, probably due to

Combinational delivery of miRNA

US

4.3.6
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immune effector T-lymphocytes.

The microRNAs (miRNAs), small non-coding RNA molecules involved in post-transcriptional
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regulation of gene expression, have been explored for combinational delivery since alterations in

M

miRNA profiles were shown to mediate multiple activities leading to tumor formation, growth and
dissemination [162, 163]. miRNAs have been delivered in combination with DNA expression vectors
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and siRNA, as well as miRNA combinations [56, 70, 164]. Co-expressing plasmid constructs for
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miRNA expression have been employed in both in vitro and in vivo models [70]. In situ expression of
miR-125b and miR-146a were shown to display anti-tumor and pro-inflammatory activity via
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macrophage polarization and activation [165, 166]. miR-125b was delivered along with p53 from an
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expression plasmid to lung cancer cells using CD44/EGFR-targeting NPs formulated using HA, PEI
and PEG [70]. The change in tumor microenvironment was evident by an increase in pro-inflammatory
mediators. Combinational delivery of a plasmid expressing p53 with miR-125b did not interfere with
each other’s activities, so that apoptotic effect of p53 reduced tumor progression, which was further
enhanced by miR-125b mediated down-regulation of anti-apoptotic proteins such as Bcl-2.
Co-delivery of miRNA with siRNAs could be advantageous due to similarity in composition of
the compounds. Successful delivery of a miR-34a mimic (a p53-regulated tumor suppressor miRNA)
and a siRNA targeting KRAS was explored in lung adenocarcinoma cells [164]. Adenocarcinoma, the
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most common Non-Small Cell Lung Cancer (NSCLC) subtype, is associated with frequent mutation in
KRAS (20-30%) and TP53 (~50%) [167]. Two specific tumor-suppressive miRNAs (e.g. let-7 and
miR-34) are significantly altered in NSCLC, so that their suppression is particularly relevant to
oncogenic phenotype of these cells [168]. The combination of miR-34a and KRAS siRNA led to tumor
regression, more significantly than the individual agents alone; miR-34a targeted gene expression was
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down-regulated and KRAS expression and MAPK signaling was suppressed. Another study reported
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co-delivery of the tumor suppressive miR-34 and let-7 for lung cancer therapy [56]. Delivery of
exogenous let-7 was reported to prevent and treat KRAS-driven lung tumor, and miR34 can prevent

US

initiation and progression of KrasG12D+/p53R172H/+ lung tumor and NSCLC xenografts [169, 170]. miR34 and let-7 combination resulted in superior reduction of proliferation and invasion in vitro, and
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systemic delivery of the combination demonstrated suppression of tumor growth in vivo, conferring a
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prolonged survival in the NSCLC mouse xenograft model. The combination delivery was able to

Nucleic acid combination in clinical use

PT

5

ED

silence the over-expressed mRNA levels of Myc, Lin28A and Lin28B.

In the case of local delivery, a carrier might not be needed since a therapeutic can be
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administered to an exposed tissue such as the eye, lung and skin [171]. However, targeting of
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therapeutic agents to other tissues often require systemic delivery and a carrier suitable for clinical use
is paramount [171]. Clinically relevant RNAi-mediated gene silencing was first reported with a
liposomal siRNA formulation in non-human primates in 2006 [172]. Since then, a number of RNAibased strategies have entered clinical trials [173]. Most carriers are mainly based on SNALPs, with the
exception of CALAA-01, a cyclodextrin-based system with transferrin mediated targeting [174, 175].
Cationic liposomes such as AtuPLEX and SNALPs represent most advanced carriers since they contain
several components [176]. Currently, the only NP system for combination therapy is ALN-VSP
(Alnylam), which is a SNALP-formulated siRNAs targeting VEFG and KSP for advanced solid tumor
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with involvement of liver metastases. Both siRNAs were modified chemically for a reduced immune
stimulation. The NPs are 80 to 100 nm in size, have a near neutral charge and distributes primarily to
liver and spleen following intravenous administration. RNAi mediated VEGF mRNA cleavage was
found in the liver of 2 patients, though this was not conclusive in patients due to the presence of other
tissue types in the biopsies. Although no dose response was observed, substantial decrease of tumor
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blood flow was observed in nearly half of the patients with evaluable liver tumors, which may be due

CR

to VEGF down-regulation. It is important to note that the lack of dose response may suggest the
possibility of nonspecific effect of SNALP formulation or premedication regime rather than a specific

US

effect of the therapy. Furthermore, patients treated with ALN-VSP showed a decreased spleen volume,
which may be indicative of anti-KSP effect [177]. No further reports have been published since 2013,
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and it is not clear if this formulation is being pursued.

Conclusions and Future Perspectives

ED

It is a widely accepted now that cancer is a heterogeneous disease, which suggests that no

PT

matter what mediator we select to target, there is a chance that a sub-population of cells would be
unresponsive to the therapy, and be selected to expand into non-responsive cells. On the other hand, the

CE

plasticity of the malignant cells highlights the risk of post-treatment adjustments that could render a

AC

previously responsive cell population resistant to any treatment. This inherent heterogeneity and
plasticity inevitably necessitates combinatorial approaches. While combinational therapy is routine for
small molecule drugs, the same cannot be stated for nucleic acids, which is largely due to limited
clinical experience with this type of therapeutic agents. The growing interest in combinational therapy
arises from the potential of synergism between carefully selected therapeutic agents, which generates
higher efficacy compared to the sum of individual constituents with presumably no additional side
effects. There is a potentially equal probability of additive as well as antagonistic effect if the
therapeutic pairs are improperly selected. Cationic, lipophilic carriers will be vital for the success of
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such combinations since they can anchor both agents into a single carrier and enhance delivery through
the lipophilic plasma membrane. However, due to competitive electronegative charge density, it is a
major task to simultaneously load short RNAs and longer DNA-based expression vectors into a single
NP.

Continuous development of new functional polymers

could generate wide varieties of

multifunctional NPs. For co-delivery of nucleic acid combinations, release kinetics of individual agents
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need to be optimized; for example, targeting certain signaling mediators generate more effective

CR

actions only after significant silencing of synergistic targets. Subsequent delivery may be more
effective than simultaneous delivery in this case [178]. To capitalize on the incredible opportunity for

Nano-Formulations with Proper Composition

AN

6.1

US

discovering suitable combinational therapies, certain fundamental issues need to be addressed.

M

Nano-formulation of therapeutic agents with carriers generally results in polydisperse NPs, that
may display differential activities due to variable stability, cargo content and surface features. Loading

ED

efficacy of the carriers may depend on different factors such as cationic charge density, hydrophobicity,

PT

and MW, so that exquisite control over starting carrier materials might be needed. Further variations in
electronic charge density and solubility among the therapeutic agents create significant variation in

CE

loading efficacy. Therefore, formulation stoichiometry may not always be translated into NP

AC

composition. It is a challenging issue to design the appropriate vehicle with proper amount of
therapeutic pairs to ensure proper efficiency. For an effective systemic outcome, delivery with higher
half-life in citculation is more critical than to ensure better accumulation in tumor environment. To
minimize opsonization in blood stream and renal-clearance, it is critical for the NPs to be stable and
remain homogenous (not segregate into constituents) despite the inherent incompatibilities between the
therapeutic combinations [179]. Many delivery experts firmly believe in “one drug, one carrier”,
implying that there is an optimum carrier for any given drug. This potentially means that any given
carrier might be less than optimal for at least one of the components of the combination. This may
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result in pre-mature release and/or degradation of the component, or insufficient release of the
component due to over-stability of the carrier/cargo interaction. Multi-component delivery systems,
with the possibility of compartmentalization, could be an effective approach, where lipids, peptides,
and/or hydrophilic moieties might provide an optimal milieu for individual components of the
combination. Finding the optimal carrier(s) for a combination of nucleic acids will certainly pose a

6.2

Delivery in Concert with Therapeutic Activity
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major challenge to overcome before we can effectively utilize this type of combinational therapy.

US

For a better translation of combination therapy to clinical setting, it is important: (1) to
completely understand the cell signaling network and especially the crosstalk among pathways, so that

AN

the proper combination of therapeutic agents can be chosen, and (2) to match the cellular exposure of

M

individual therapeutics to the order and duration of desired activity [178]. A properly matched
combination may lead to strong synergism while an un-match treatment might generate antagonistic

ED

effects. So far, most of the efforts in this regard have been arbitrary selections, while more systematic

PT

studies are required to identify potential targets for ideal combinations. These targets could be selected
to enhance the therapeutic effect by affecting multiple factors involved in the same mechanism, or to

CE

affect alternative mechanisms to block other options for cell survival. Due to convenience of

AC

administrating multiple agents at the same time, simultaneous delivery is more commonly pursued for a
therapeutic effect, as compared to sequential administration. To realize a proper balance between
release kinetics of individual therapeutic agents and their therapeutic activity, NPs derived from layerby-layer fabrication might be desirable to control the release of different agents at different duration
[180].

6.3

siRNA-Related Off-Target Effects
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Sequence-specific off-target effects related to siRNA (and miRNA) is a critical issue in
combinational therapy. siRNA may initiate off-target gene silencing by hybridizing with other mRNA
targets and interfacing with the miRNA network [171, 181]. Off-target effects induced by binding to
proteins,

specifically to immune-activating receptors such as toll-like receptors, can lead to

inflammation [171, 181]. To control specificity of siRNA and minimize off-target potential, careful

increase

the

opportunity to

knockdown the desired

target gene(s),

and

provide
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silencing,
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design of the oligonucleotides is imperative. Dual-targeting may reduce the potential for off-target gene

additive/synergistic effect by both oligonucleotides [171]. Using a breast cancer cell model, we showed

US

that efficiency of double silencing with siRNA is reserved and it is usually similar to the single
targeting (Figure 9). Combinational delivery will be particularly beneficial if the effective dose of the

AN

agents could be reduced as a result of synergistic effects. Changes in non-targeted mediators, however,

M

has been often observed after delivering siRNA against other targets (Figure 9). This will be important
if a critical mediator is altered significantly as a by-stander and measures to minimize such an

ED

interference might be necessary if the outcome is undesirable. Alternatively, one can attempt to predict

PT

the molecular vulnerabilities of malignant cells from known signaling networks [182], and target most

AC

possible side-effects.

CE

effective combinations (i.e., vulnerable) of targets to minimize the therapeutic agents to reduce any
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Figure 9. Dual targeting with siRNA combinations in a breast cancer model (data adopted from
Left. Changes in target mRNA levels as a result of single or combinational siRNA

US

reference [183]).

treatment. JAK2, STAT3, Mcl-1 and JUN mRNA levels are shown after single or combinational

AN

delivery of siRNA (e.g., blue line shows changes in JAK2 mRNA levels after delivering JAK2 siRNA
alone or JAK2 combined with STAT3, Mcl-1 and JUN siRNAs). Right. Changes in non-targeted

M

mRNA levels as a result of delivering JAK2, STAT3, Mcl-1 and JUN siRNA as a mono therapy. Note

6.4

ED

that the indicated mRNA levels were normalized with the specific mRNAs in non-treated cells.

Delivery System Limitations for Nucleic Acids

PT

A critical limitation in combinational therapy is the lack of an efficient delivery system for

CE

nucleic acids to target specific cells [171]. The most clinically advanced synthetic delivery systems are
engineered for well-perfused tissues such as the liver, kidney and some solid tumors, where fenestrated

AC

or discontinuous endothelium allow the passage of NPs to target tissues [171, 173]. However, delivery
to less accessible tissues remains a considerable challenge [181]. Even with systemically present
leukemias, there is a need for specific delivery to malignant cells (vs. normal hematopoietic cells),
whose challenges has been previously articulated in the context of siRNA delivery [173, 184]. For
selective targeting to tumor or other tissues, careful modulation of physical properties, such as stealth
properties of spherical particles, size (<100 nm in diameter), or affinity (with specific targeting ligands)
will be required to control the ideal distribution of therapeutic agents. Target selection is another
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approach in minimizing unwanted effect in non-targeted tissue. Specific proteins might play a pivotal
role in the survival and/or resistance of malignant cells, but they play a significantly less important role
in healthy cells. Alternatively, quantitative differences in protein targets between malignant and normal
cells may skew the action of nucleic acid therapies where the target level if elevated. Selection of these
targets will help limit the effect to malignant cells, since the healthy cells would not respond the same

CR

IP

T

way, even if the targeted proteins are affected.
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Table 1. Summary of nucleic acid combinations employed in cancer therapy
Combination

Vehicle

Targets

Outcome

GPCS

Lung cancer
In vitro: A549 and
H460 Cells
In vivo: BALB/c mice
Lung cancer
In vitro: NSCLC cells
In vivo: H322 lung
cancer mouse
Glioblastoma
In vitro: U251-MG
cells
In vivo: BALB/c mice

DOTAP/
Cholesterol
NPs

Lipofectami
ne

Express shRNAEHFR/PTEN: down
regulate EGFR and
up-regulation of PTEN

shRNASTAT3/ LKB1

Ovarian cancer
In vitro: SKOV3 cells
In vivo: BALB/c mice

Lipofectami
ne

Express shRNA-STAT3
and LKB1: upregulate
p21 and p-p53, silence
MMP-2 and MMP-9

Induce apoptosis,
reduces invasion,
migration and tumor
growth

shRNASURVIVIN/ GR
IM-19

Laryngeal cancer
In vitro: Hep-2 cells
In vivo: BALB/
c-nu/nu nude mice
Thyroid carcinoma
In vitro: SW579 cells
In vivo: BALB/c nude
mice
Breast cancer
In vitro: MDA435
In vivo: Nude Mice
Prostate cancer, Breast
cancer
In vitro: PC-3, MDAMB-231 cells
In vivo: Mouse model
Breast Cancer
In vitro: MDA-MB-231
Cells
Breast cancer
In vitro: MCF7 Cells

Lipofectami
ne

Express shRNASURVIVIN and GRIM19: silence SURVIVIN
and STAT-3
Express shRNA-STAT3
and GRIM-19: silence
STAT3, MMP-2, MMP9, VEGF expression
Down regular target gene

Inhibit the growth and
induce the apoptosis of
Hep-2 cells

Silence VEGF, Bcl-2,
SURVIVIN expression

Increase apoptosis, and
inhibited tumor growth

[14] [73]

Inhibit cell growth

[68]

Lipofectami
ne

Silence TTK, DCD20
and SURVIVIN
expression
Silence VEGF and HER2
expression

[145]

Gastric Cancer
In vitro: SGC-7901
cells

Lipofectami
ne

Silence VEGF and HER2
expression

Mammary cancer
In vitro: BJMC3879
cell
In vivo: BALB/c mice
Hepatocellular
carcinoma
In vitro: Hep3B cells

Electrotransfer

Silence VEGF-C and
VEGF-A expression

Inhibit invasion,
proliferation and
induce apoptosis
Inhibit cell
proliferation,
migration, and induce
apoptosis
Reduce metastasis and
enhance survival of
mice

Lipofectami
ne

Silance KSP, Cyclin D1,
Bcl-2, SURVIVIN

p-gp/Mcl-1/
RPS6KA5
siRNA
VEGEF/ Bcl-2
or SURVIVINsiRNA

TTK/CDC20,
CDC20/SURVI
VIN
VEGEFsiRNA/HER2siRNA
VEGEFsiRNA/HER2siRNA
psiRNAVEGEF-C+A

VEGEFsiRNA/KSPsiRNA

Lipofectami
ne

PEIDerivatives
GC, LPEI25

PEIDerivatives

Induce mitochondriamediated apoptosis

T

Induce apoptosis and
enhance survival of
mice

[15]

[54]

Induce apoptosis and
suppress tumor growth

[57]

Induce apoptosis and
suppress tumor growth

[13]
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shRNASTAT3/GRIM19
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shRNAEGFR/PTEN

DOTAP:
Cholesterol
NPs

PT

FUSI/p53

CE

LKB1/FUS1

Co-expression of
LETM1 and CTMP,
activate AMPK and Akt1
pathways
Co-expression of LKB1
and FUS1, upregulates pp53, p-aMPK and silence
p-mtOR
Silence MDM2, and
upregulate Apaf-1

Ref.

Hepatocellular
carcinoma
In vivo: H-ras12V mice

AC

LETM1/CTMP

Cancer type/Model

Induce apoptosis,
reduces invasion,
migration and tumor
growth
Induce apoptosis and
inhibit tumor growth

Inhibit growth,
migration, invasion
and induce apoptosis of

[41]

[120]

[123,
124]

[26, 30]

[146]

[185]

[148]
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tK/mGMCSF/mIL-2
GC-CSF/IL-2

HSV-tk/mIL-2

IL-12, pro-IL18, and ICE
cDNA

Up-regulate caspase-3
activities

Hepatocellular
carcinoma
In vitro: HepG2 cells
In vivo: BALB/c mice
Colorectal cancer
In vitro: DLD-1, Caco2
cells
Nasopharyngeal cancer
In vitro: CNE2 and
TW03 cells
Lung cancer
In vitro: NSCLC cells
In vivo: Mice model
Lung cancer
In vitro: SK-LU-1 cells
In vivo: KP mice
Lung cancer
In vitro: KP cells
In vivo: KP Mice

Lipofectami
ne

Silence VEGF
expression

Oligofectam
ine

Up-regulate caspase-3/7
activities

Lipofectami
ne

Silence EGFR and
IGF1R mRNA and
protein expression
Repress oncogene
expression

Colon cancer
In vivo: BALB/c Mice
Squamous cancer
In vitro: SCCVII
In vivo: C3H/HeJ mice
Colon carcinoma
In vivo: BALB/c Mice

Virus

In vivo: BALB/c mice

HAPEI/PEG
Polyplexes

Increase APAF-1
expression and caspase-3
activity, Silence Bcl-2
Restore P53 activity,
reduce KRAS gene
expression and MAPK
signaling
Express tK/mGM/mIL-2

DISC
viruses

Secret GC-CSF/IL-2

Virus

Express HSV-tK/mIL-2

Gene gun

Inhibit cell
proliferation and
induce apoptosis
Inhibit growth and
angiogenesis of HCC,
suppress tumor growth

T

Inhibit cell
proliferation and
induce apoptosis
Induce apoptosis and
chemo-sensitivity
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DharmaFEC
T1

AN

miRNA/siRNA

Lipofectami
ne

M

plasmid (wtp53+miR-125b)

Silence target gene
expression

[149]

TM

ED

IGF-IRsiRNA/EGFRsiRNA
pU6-EGFRshRNA/pU6IGF1R-shRNA
miR-34/let-7

INTERFERi
n

PT

Bcl-2
/SURVIVINsiRNA
VEGF-NET-1
siRNA

HCC cells
Increase anti-cancer
activity

Lung cancer
In vitro: MSTO-211H,
NCI-H28 and
NCI-H2052 cells
Human bladder cancer
In vitro: T24 cells

Inhibit cell
proliferation and tumor
growth
Reduce tumor
progression and
proliferation
Increase apoptosis,
Inhibited tumor growth

Enhance antitumor
immunity
Suppress tumor growth

[150]

[151]

[55]

[160]

[56]

[70]

[164]

[42]

[43]

Induce INF-γ pathway

Reduce metastasis of
colon carcinoma into
liver
Enhance antitumor
activity

[40]

[161]

CE

Bcl-2/Mcl-1

AC

Abbreviations: LETM1: Leucine zipper/EF hand-containing transmembrane-1, CTMP: carboxyl-terminal
modulator protein, GPCS: galactosylated poly (ethylene glycol)-chitosan-graft-spermine, VEGF: Vascular
endothelial growth factor, Bcl2: B-cell lymphoma2, GC: glycol chitosan NPs, KRAS: Kirsten rat sarcoma viral
oncogene homolog, LKB1: liver kinase B1, STST-3: signal transducer and activator of transcription 3, FUSI:
tumor suppressor candidate 2, DOTAP: N-[1-(2,3-dioleoyloxyl) propyl]-NNN-trimethylammoniummethyl
sulfate, MDM2: murine double minute-2, Apaf-1: apoptotic protease-activating factor 1, EGFR: epidermal
growth factor receptor, PTEN: Phosphatase and tensin homolog, HER-2: human epidermal growth factor
receptor 2, NET-1: Neuroepithelial cell-transforming gene 1 protein, KSP: kinesin spindle protein, PEI25:
Polyethylenimine (MW 25,000 Da), IGF-IR: insulin-like growth factor I(IGF-I) receptor, HSV-tk: herpes
simplex virus thymidine kinase, mIL-2: mouse interleukin-2, mGM-CSF: mouse granulocyte macrophage
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colony-stimulating factor, GC-CSF: granulocyte-macrophage colony-stimulating factor, DISC: 2-defective
infectious single-cycle (DISC) viruses, IL2: Interleukin-2, NSCLC: non–small cell lung cancer, VEGF-C:
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Vascular endothelial growth factor-C, VEGF-A: Vascular endothelial growth factor-A.
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